Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Locoregional Radiotherapy in Metastatic Nasopharyngeal Cancer—Reply

Locoregional Radiotherapy in Metastatic Nasopharyngeal Cancer—Reply Letters Debiopharm, Bristol Myers Squibb, Nanobiotix, Tilos, AstraZeneca, LEK, earlier time points following N+I, this difference was not sta- Catenion, ACI Clinical, and Immunitas; and expert witness fees outside the tistically significant, and the timing of events did not appear submitted work. Dr Uppaluri reported receiving grants from Bristol Myers to influence toxic effect severity or resolution with treat- Squibb during the conduct of the study and serving on a Merck Scientific ment—which were similar in both arms. With the limited Advisory Board outside the submitted work. Dr Haddad reported consulting for Bristol Myers Squibb, Merck, AstraZeneca, Pfizer, GlaxoSmithKline, Genentech, numbers of patients in our study, we cannot make broad con- Celgene, and Bayer and receiving research support from GlaxoSmithKline, clusions regarding safety of N+I in this setting or exclude the Merck, Bristol Myers Squibb, Pfizer, AstraZeneca, Genentech, and Kura outside possibility that a larger study might identify a more concern- the submitted work. ing safety profile. However, most importantly and with 1. Schoenfeld JD, Hanna GJ, Jo VY, et al. Neoadjuvant nivolumab or nivolumab respect to the safety primary end point, there were no dose- plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Locoregional Radiotherapy in Metastatic Nasopharyngeal Cancer—Reply

JAMA Oncology , Volume 7 (2) – Mar 2, 2021

Loading next page...
 
/lp/american-medical-association/locoregional-radiotherapy-in-metastatic-nasopharyngeal-cancer-reply-Ig60q7NCLg
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.7017
Publisher site
See Article on Publisher Site

Abstract

Letters Debiopharm, Bristol Myers Squibb, Nanobiotix, Tilos, AstraZeneca, LEK, earlier time points following N+I, this difference was not sta- Catenion, ACI Clinical, and Immunitas; and expert witness fees outside the tistically significant, and the timing of events did not appear submitted work. Dr Uppaluri reported receiving grants from Bristol Myers to influence toxic effect severity or resolution with treat- Squibb during the conduct of the study and serving on a Merck Scientific ment—which were similar in both arms. With the limited Advisory Board outside the submitted work. Dr Haddad reported consulting for Bristol Myers Squibb, Merck, AstraZeneca, Pfizer, GlaxoSmithKline, Genentech, numbers of patients in our study, we cannot make broad con- Celgene, and Bayer and receiving research support from GlaxoSmithKline, clusions regarding safety of N+I in this setting or exclude the Merck, Bristol Myers Squibb, Pfizer, AstraZeneca, Genentech, and Kura outside possibility that a larger study might identify a more concern- the submitted work. ing safety profile. However, most importantly and with 1. Schoenfeld JD, Hanna GJ, Jo VY, et al. Neoadjuvant nivolumab or nivolumab respect to the safety primary end point, there were no dose- plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label

Journal

JAMA OncologyAmerican Medical Association

Published: Mar 2, 2021

References